The Danish nationwide registry analysis of nearly 150,000 adults initiating semaglutide for weight management between late 2022 and mid-2024 shows a modest reversal in rising triptan consumption after one year, concentrated among women already using acute migraine therapies. This observational design, while leveraging comprehensive population data for strong temporal trends, lacks randomization and cannot isolate semaglutide's direct effects from concurrent weight loss or lifestyle changes. Collaboration with Novo Nordisk introduces clear conflicts of interest that warrant scrutiny in interpreting the 8% triptan reduction seen only in females. Prior observational work, such as the 2024 Headache journal cohort linking GLP-1 agonists to lowered CGRP levels via reduced neuroinflammation, supports a plausible intracranial-pressure and cytokine pathway, yet that smaller sample (n=312) also remained non-randomized. An earlier 2023 RCT in Neurology (n=84) testing liraglutide found similar severity drops but highlighted pharmacokinetic sex differences in drug exposure. What the original coverage underplays is the absence of any preventive effect on incident migraine cases and the risk that benefits may fade once weight stabilizes. These patterns align with emerging evidence of GLP-1 receptor expression in hypothalamic and trigeminal regions, suggesting future targeted trials should stratify by sex and migraine subtype rather than defaulting to broad obesity indications.